SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

BRIEF-Abbvie Says New Data Demonstrates Co's Venclyxto/Venclexta Combination Sustained Progression-Free Survival In Chronic Lymphocytic Leukemia Patients

reuters.com · 06/10/2022 01:08
BRIEF-Abbvie Says New Data Demonstrates Co's Venclyxto/Venclexta Combination Sustained Progression-Free Survival In Chronic Lymphocytic Leukemia Patients

- Abbvie Inc ABBV:

  • NEW DATA DEMONSTRATES ABBVIE'S VENCLYXTO®/VENCLEXTA® COMBINATION SUSTAINED PROGRESSION-FREE SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AFTER FOUR YEARS OFF TREATMENT

  • PFS WAS SIGNIFICANTLY SUPERIOR FOR VENETOCLAX PLUS OBINUTUZUMAB COMPARED TO CHLORAMBUCIL PLUS OBINUTUZUMAB

Source text for Eikon: ID:nPnbrMZwDa

Further company coverage: ABBV


((Reuters.briefs@thomsonreuters.com;))